Clinical evaluation of commercial PCR assays for antimicrobal resistance in Mycoplasma genitalium and estimation of resistance-mediated mutation prevalence in Moscow and Moscow region
- PMID: 33515097
- DOI: 10.1007/s10096-021-04170-0
Clinical evaluation of commercial PCR assays for antimicrobal resistance in Mycoplasma genitalium and estimation of resistance-mediated mutation prevalence in Moscow and Moscow region
Abstract
Mycoplasma genitalium is a widespread sexually transmitted infection (STI) with growing rate of antimicrobials resistance. In our study, 137 vaginal and 131 urethral M. genitalium-positive swabs were sequentially collected through the work of Reference Center for STI during 2019. For prevalence evaluation of macrolide-resistance mutations three commercially available kits were used: AmpliSens® M. genitalium-ML/FQ-Resist-FL (Central Research Institute of Epidemiology, Russia), ResistancePlus® MG (SpeeDx, Australia), and S-DiaMGRes™ (Diagenode, Belgium). Macrolide resistance mutations were detected in 16% (43 of 268) of samples. Diagnostic characteristics were evaluated against Sanger sequencing. For AmpliSens® M. genitalium-ML/FQ-Resist-FL specificity was shown to be 100% (CI 95%, 98.4-100), and sensitivity was 90.7% (CI 95%, 77.9-97.4). ResistancePlus® MG specificity was 100% (CI 95%, 98.3-100), and sensitivity was 92.1% (CI 95%, 78.6-98.3). S-DiaMGRes™ specificity was shown to be 88.6% (CI 95%, 83.9-92.4), and sensitivity was 100% (CI 95%, 84.4-100). Mutations of parC gene region were detected in 14.5% (38 of 268) using AmpliSens® M. genitalium-ML/FQ-Resist-FL with further validation by Sanger sequencing. Of studied samples, 6.3% (17 of 268) contained both antimicrobials of class resistance mutations. Prevalence of macrolide-resistant M. genitalium in Moscow was 21.7% (23 of 106) and of fluoroquinolone-resistant M. genitaliuim was 20.8% (22 of 106). In Moscow region, macrolide-resistant M. genitalium were 12.3% (20 of 162) and 9.9% (16 of 162) of fluoroquinolone-resistant M. genitalium. All three kits can be used both for epidemiological monitoring of M. genitalium presence and mutation prevalence estimation. In Moscow, macrolide- and fluoroquinolone-resistant mutant prevalence increased in 3.9 and 2.7 times in 3 years.
Keywords: 23S rRNA; Antibiotic resistance gene determinants; Fluoroquinolone; Macrolide; Molecular diagnostics; Mycoplasma genitalium; PCR; QRDR.
References
-
- Taylor-Robinson D, Jensen JS (2011) Mycoplasma genitalium: from chrysalis to multicolored butterfly. Clin Microbiol Rev 24:498–514. https://doi.org/10.1128/CMR.00006-11 - DOI - PubMed - PMC
-
- Tully J, Cole R, Taylor-Robinson D, Rose D (1981) A newly discovered mycoplasma in the human urogenital tract. Lancet 317:1288–1291. https://doi.org/10.1016/S0140-6736(81)92461-2 - DOI
-
- Baumann L, Cina M, Egli-Gany D, Goutaki M, Halbeisen FS, Lohrer G-R et al (2018) Prevalence of Mycoplasma genitalium in different population groups: systematic review andmeta-analysis. Sex Transm Infect 94:255–262. https://doi.org/10.1136/sextrans-2017-053384 - DOI - PubMed - PMC
-
- Lis R, Rowhani-Rahbar A, Manhart LE (2015) Mycoplasma genitalium infection and female reproductive tract disease: a meta-analysis. Clin Infect Dis 61:418–426. https://doi.org/10.1093/cid/civ312 - DOI - PubMed
-
- Napierala Mavedzenge S, Weiss HA (2009) Association of Mycoplasma genitalium and HIV infection: a systematic review and meta-analysis. AIDS 23:611–620. https://doi.org/10.1097/QAD.0b013e328323da3e - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical